Evolus Q3 Revenue Surges 22% to $61.1M, Wins EU Approval for …

Nov 6, 2024 · Evolus (NASDAQ: EOLS) reported Q3 2024 total net revenue of $61.1 million, up 22% from Q3 2023, with year-to-date growth of 33%. The company received EU approval for Estyme® Injectable Hyaluronic Acid Gels, with launch expected in H2 2025. Evolus narrowed …

22%
OFF

Evolus Q3 Revenue Surges 22% To $61.1M, Wins EU Approval For …

1 week from now

stocktitan.net

29%
OFF

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge …

1 week from now

2024 Revenue Guidance: Narrowed to $260 million to $266 million, representing 29% to 32% growth year-over-year. Adjusted Gross Profit Margin Guidance: 68% to 71% for 2024.

yahoo.com

22%
OFF

Evolus, Inc. Reports Strong Q3 2024 Growth - Nasdaq

1 week from now

Nov 7, 2024 · Evolus recently reported its financial results for the third quarter of 2024, highlighting a 22% increase in total net revenue, reaching $61.1 million compared to Q3 2023.

nasdaq.com

22%
OFF

Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge …

1 week from now

Nov 7, 2024 · Evolus Inc (NASDAQ: EOLS) achieved a 22% increase in net revenue for the third quarter, reaching $61 million, which is significantly above market growth. The company …

investing.com

12%
OFF

Evolus Revenue 2015-2024 - Stock Analysis

1 week from now

Nov 13, 2024 · Evolus had revenue of $61.09M in the quarter ending September 30, 2024, with 22.12% growth. This brings the company's revenue in the last twelve months to $248.33M, up …

stockanalysis.com

22%
OFF

Evolus, Inc. Reports Strong Q3 2024 Growth | Markets Insider

1 week from now

Nov 7, 2024 · Evolus recently reported its financial results for the third quarter of 2024, highlighting a 22% increase in total net revenue, reaching $61.1 million compared to Q3 2023.

businessinsider.com

12%
OFF

Evolus Revenue - Stock Analysis

1 week from now

4 days ago · Evolus had revenue of $61.09M USD in the quarter ending September 30, 2024, with 22.12% growth. This brings the company's revenue in the last twelve months to …

stockanalysis.com

$61
OFF

Evolus Reports Q3 EPS (30c), Consensus (10c) - Nasdaq

1 week from now

Sep 13, 2024 · Reports Q3 revenue $61.1M, consensus $62.2M. "Our third quarter results underscore the momentum we’ve been building throughout the year," said David Moatazedi, …

nasdaq.com

22%
OFF

2024-11-06 | Evolus Reports Third Quarter 2024 Results

1 week from now

Nov 6, 2024 · Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33%; Received Approval for Estyme &circledR; Injectable Hyaluronic Acid …

stockhouse.com

12%
OFF

(EOLS) Evolus Revenue: 2015-2025 Annual Revenue - WallStreetZen

1 week from now

Evolus revenue was $248.33M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. ... EOLS) reported Q3 2024 revenue of $61.09 million up 22.12% year over …

wallstreetzen.com

22%
OFF

Evolus Reports Third Quarter 2024 Results - Morningstar

1 week from now

Nov 6, 2024 · Evolus Reports Third Quarter 2024 Results. Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33%; Received Approval for Estyme …

morningstar.com

$61
OFF

Evolus Reports Q3 EPS (30c), Consensus (10c) | Markets Insider

1 week from now

Nov 6, 2024 · Reports Q3 revenue $61.1M, consensus $62.2M. “Our third quarter results underscore the momentum we’ve been building throughout the y...

businessinsider.com

$1
OFF

Evolus Gets EU Approval For Treatment Of Wrinkles

1 week from now

Certification of the treatment Estyme--branded as Evolysse in the U.S. market--is a key regulatory milestone, enabling it to double its addressable market outside of the U.S. to $1.8 billion, the ...

marketwatch.com

$260
OFF

Evolus Maintains Strong Growth Outlook Despite Earnings Miss: A …

1 week from now

Nov 7, 2024 · Evolus reports Q3 EPS (30c), consensus (10c) Evolus sees FY24 revenue $260M-$266M, consensus $266.1M Evolus says Estyme receives EU Medical Device Regulation …

businessinsider.com

22%
OFF

Evolus Reports Third Quarter 2024 Results - FT.com

1 week from now

Nov 6, 2024 · Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33%; Received Approval for Estyme ® Injectable Hyaluronic Acid (HA) Gels in …

ft.com

FAQs about Evolus Q3 Revenue Surges 22% to $61.1M, Wins EU Approval for … Coupon?

How did Evolus perform in Q3 2024?

Evolus recently reported its financial results for the third quarter of 2024, highlighting a 22% increase in total net revenue, reaching $61.1 million compared to Q3 2023. The company is experiencing significant growth, driven by consumer engagement and innovative product launches, with a notable expansion into the European market. ...

How much will Evolus make in 2024?

Evolus has narrowed its full-year 2024 net revenue guidance to between $260 million and $266 million, indicating a year-over-year growth of 29% to 32%. The company is preparing for the U.S. launch of its Evolysse™ injectable HA gels, with FDA approval expected by September 2025, and anticipates reaching $700 million in revenue by 2028. ...

Will Evolus bolster its market presence in 2024?

Despite a recorded loss from operations, the company’s strategic growth initiatives and new product launches are set to bolster its market presence. Evolus has narrowed its full-year 2024 net revenue guidance to between $260 million and $266 million, indicating a year-over-year growth of 29% to 32%. ...

How did Evolus perform in the third quarter?

Evolus Inc (NASDAQ:EOLS) added over 600 purchasing accounts in the third quarter and maintained a strong reorder rate of over 70%. The Evolus Rewards program surpassed 1 million consumers enrolled, demonstrating strong consumer engagement and loyalty. ...

Will Evolus launch evolysse in the US by September 2025?

The company is on track to launch Evolysse in the U.S. by September 2025, with expectations of further market expansion and operating margin growth. Evolus Inc (NASDAQ:EOLS) reported a non-GAAP operating loss of $6.7 million in the third quarter, compared to a non-GAAP operating income of $1.1 million in the second quarter. ...

Does Evolus offer injectable hyaluronic acid gels?

With its innovative digital platforms and customer-centric model, Evolus is expanding its portfolio with injectable hyaluronic acid gels. Evolus recently reported its financial results for the third quarter of 2024, highlighting a 22% increase in total net revenue, reaching $61.1 million compared to Q3 2023. ...